Phase 3 Progression Clinical Trials
8 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–8 of 8 trials
Recruiting
Phase 3
The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children
Myopia Progression
Aston University66 enrolled1 locationNCT07535749
Recruiting
Phase 3
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
First Progression of Glioblastoma
European Organisation for Research and Treatment of Cancer - EORTC411 enrolled43 locationsNCT05904119
Recruiting
Phase 3
Atropine in the Treatment of Myopia Study in Malaysia
Myopia Progression
IDB VisionCare SDN BHD144 enrolled2 locationsNCT07329777
Recruiting
Phase 3
Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
HIV Disease Progression
Population Health Research Institute8,000 enrolled52 locationsNCT05580666
Recruiting
Phase 3
Omitting CTV for Primary Tumor in LS-SCLC
Radiotherapy Side EffectProgressionSCLC, Limited Stage+1 more
Sun Yat-sen University852 enrolled2 locationsNCT07008716
Recruiting
Phase 3
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression
MyopiaMyopia Progression
Oupushifang Pharmaceutical Technology Co., Ltd.606 enrolled25 locationsNCT06708156
Recruiting
Phase 3
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
Advanced CancerOlanzapineProgression Free Survival
Qinghai Red Cross Hospital230 enrolled1 locationNCT06338683
Recruiting
Phase 3
A Phase 3 study comparing the combination of CAELYX and YONDELIS (the study drug) with CAELYX alone in subjects with advanced relapsed ovarian cancer who have previously had platinum based chemotherapy treatment (eg. Carboplatin/Cisplatin)
Advanced relapsed Ovarian Cancer - to prolong progression free survival
Johnson & Johnson Pharmaceutical Research & Development650 enrolled1 locationACTRN12607000169448